1-18 of 18
M Ruiz-Borrego
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract OT3-06-01: Phase Ib clinical trial of co PAN lisib in combination with T rastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER 2-positive bre A st cancer (BC) “PANTHERA”-CTRIAL-IE 17-13

A Hassan, G Gullo, S O'Reilly, M Ruiz-Borrego, S Toomey, L Grogan, O Breathnach, PG Morris, JM Walshe, J Crown, D O'Mahony, A Falcon, K Egan, A Hernando, A Teiserskiene, CM Kelly, L Coate, BT Hennessy
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT3-06-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-OT3-06-01
Published: 15 February 2019
View article
Journal Articles

Abstract P1-14-01: Final results of NorBreast-231, a randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel as first-line chemotherapy in patients with advanced breast cancer

MS Aapro, R Hegg, M Ruiz Borrego, E Staroslawska, S Morales, S Cinieri, R De Freitas Junior, L Garcia Estevez, E Szombara, H Hervieu, M Groc, GR Villanova
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P1-14-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P1-14-01
Published: 15 February 2019
View article
Journal Articles

Abstract P2-08-06: Standardized nCounter-based determination of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor status in breast cancer

T Pascual, YS Tsai, M Martín, A Lluch, J Cortes, A Llombart, P Conte, V Guarneri, MF Rimawi, E Alba, M Ruiz-Borrego, F Rojo, J de la Haba, R Schiff, B Adamo, M Vidal, L Paré, N Chic, M Muñoz, P Galvan, B Gonzalez-Farre, HA Brauer, A Sullivan, P Nuciforo, JS Parker, A Prat
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-08-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P2-08-06
Published: 15 February 2019
View article
Journal Articles

Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial

M Gnant, M Martin, F-A Holmes, C Jackisch, SK Chia, H Iwata, B Moy, N Martinez, J Mansi, S Morales, M Ruiz-Borrego, G von Minckwitz, M Buyse, S Delaloge, M Bhandari, A Murias Rosales, T Galeano, T Fujita, A Luczak, CH Barrios, C Saura, HS Rugo, J Chien, SR Johnston, M Spencer, F Xu, B Barnett, A Chan, B Ejlertsen
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-13-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P2-13-01
Published: 15 February 2019
View article
Journal Articles

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

M Martín, CH Barrios, L Torrecillas, M Ruiz-Borrego, J Bines, J Segalla, A Ruiz, JA García-Sáenz, R Torres, J de la Haba, E García, HL Gómez, A Llombart, M Rodríguez de la Borbolla, JM Baena, A Barnadas, L Calvo, L Pérez-Michel, M Ramos, J Castellanos, A Rodríguez-Lescure, J Cárdenas, J Vinholes, E Martínez de Dueñas, MJ Godes, MA Seguí, A Antón, P López-Álvarez, J Moncayo, G Amorim, E Villar, S Reyes, C Sampaio, B Cardemil, MJ Escudero, S Bezares, E Carrasco, A Lluch
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): GS2-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-GS2-04
Published: 15 February 2019
View article
Journal Articles

Abstract P1-13-05: Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial

B Ejlertsen, A Chan, M Gnant, G von Minckwitz, S Delaloge, M Buyse, J O'Shaughnessy, J Mansi, B Moy, H Iwata, A Wong, Y Ye, J Means-Powell, R Hui, M Ruiz-Borrego, A Ruiz Simon, Z-Z Shen, FA Holmes, K Lesniewski-Kmak, M Martin
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-13-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-13-05
Published: 15 February 2018
View article
Journal Articles

Abstract P6-14-03: Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

M Aapro, M Ruiz Borrego, E Staroslawska, S Morales, S Cinieri, R De Freitas Junior, L Garcia Estevez, E Szombara, H Hervieu, M Groc, G Villanova, R Hegg
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P6-14-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P6-14-03
Published: 15 February 2018
View article
Journal Articles

Abstract P5-21-23: Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study

M Martín, J Hoffman, M Ruiz-Borrego, M Muñoz, L Calvo, P Crownover, JA García-Sáenz, E Alba, D Wang, C Thallinger, A Stradella, Á Montaño, B Adamo, S Antolín, F Moreno-Antón, C Falo, V Ruiz, N Martín, R Caballero, E Carrasco, M Gil-Gil
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-21-23.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-21-23
Published: 15 February 2018
View article
Journal Articles

Abstract OT2-01-06: Phase III study of p albociclib (PD-0332991) in combination with e ndocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with r esistance to a romatase inhibitors. “The PEARL study” (GEICAM/2013-02)

M Martín, Z Kahan, E Carrasco, CH Bartlett, M Casas, M Gil-Gil, M Muñoz, EM Ciruelos, M Ruiz-Borrego, M Margelí, A Antón, B Bermejo, S Morales, E Gal-Yam, M Koehler, JA García-Sáenz, J de la Haba, I Chacón, C Zielinski
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): OT2-01-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT2-01-06
Published: 15 February 2017
View article
Journal Articles

Abstract OT3-01-02: A phase I-II trial of dasatinib in combination with trastuzumab (T) and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients: GEICAM/2010-04

A Ocaña, M Ruiz Borrego, M Gil-Martín, S Antolín, Á Guerrero, L Vidal Boixader, M Martín, JM Trigo Pérez, F Rojo, Y Jerez, M Atienza, S Pernas, A Hernando, E Carrasco, S Benito, R Caballero, A Pandiella
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): OT3-01-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-OT3-01-02
Published: 15 February 2016
View article
Journal Articles

Abstract P2-11-06: Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy - A GEICAM/ 9906 sub-study

M Martin, JC Brase, CM Perou, A Ruiz, A Prat, KE Weber, L Calvo, C Petry, PS Bernard, M Ruiz-Borrego, R Kronenwett, AM Santaballa, CA Rodriguez, IM Alvarez, MA Segui, M Casas, E Carrasco, R Caballero, A Rodriguez-Lescure
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P2-11-06.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-P2-11-06
Published: 15 December 2013
View article
Journal Articles

Abstract P3-10-02: The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM)

S Del Barco, M Muñoz, M Margeli, JI Chacon, J Cassinello, S Antolin, E Adrover, M Ramos-Vazquez, E Carrasco, MA Jimeno, B Ojeda, X Gonzalez, S Gonzalez, M Constenla, J Florian, A Miguel, A Llombart, A Lluch, M Ruiz-Borrego, R Colomer, A Barnadas
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P3-10-02.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-P3-10-02
Published: 15 December 2013
View article
Journal Articles

Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer

A Lluch-Hernández, A Ruiz Simon, C-S Huang, J Cortés Castán, M Ruiz-Borrego, M Telli, R Ismail-Khan, M Parton, L-M Tseng, S-C Chen, P Schmid, I Mayer, S Hurvitz, L García-Estévez, R Atienza, M Wu, S Cameron, JT Beck, A Bardia
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): OT1-4-04.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-OT1-4-04
Published: 15 December 2013
View article
Journal Articles

Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC)

CE Barrios, A Lluch, M Ruiz-Borrego, J Bines, L Torrecillas, E Carrasco, JGM Segalla, A Ruiz, JA Garcia-Saenz, R Torres, J De la Haba-Rodriguez, E Garcia-Martinez, S Morales, H Gomez, J Salvador-Bofill, A Hernando, M Martin
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): OT3-1-06.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-OT3-1-06
Published: 15 December 2013
View article
Journal Articles

Abstract P2-10-11: Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM/9906 trial.

M Martin, JC Brase, M Ruiz-Borrego, K Krappmann, B Munarriz, K Fisch, A Ruiz, KE Weber, C Crespo, C Petry, CA Rodriguez, R Kronenwett, L Calvo, E Alba, E Carrasco, M Casas, R Caballero, A Rodriguez-Lescure
Journal: Cancer Research
Cancer Res (2012) 72 (24_Supplement): P2-10-11.
DOI: https://doi.org/10.1158/0008-5472.SABCS12-P2-10-11
Published: 15 December 2012
View article
Journal Articles

P5-14-22: Prospective Observational Study To Describe the Clinicopathological and Biological Characteristics and the Management of Metastatic Breast Cancer Patients Who Experienced Complete or Partial Remission or Disease Stabilization during at Least 3 Years.

P Zamora, R Pérez-Carrión, L Manso, C Crespo, C Mendiola, I Alvarez-López, M Margeli, JL Bayo-Calero, X González-Farre, A Santaballa, EM Ciruelos, R Afonso, J Lao, G Catalán, JV Alvarez-Gallego, J Miramón-López, FJ Salvador-Bofill, M Ruiz-Borrego
Journal: Cancer Research
Cancer Res (2011) 71 (24_Supplement): P5-14-22.
DOI: https://doi.org/10.1158/0008-5472.SABCS11-P5-14-22
Published: 15 December 2011
View article
Journal Articles

Abstract P5-10-15: First Safety Data from a Randomised Phase III (CIBOMA 2004- 01/GEICAM 2003-11) Trial Assessing Adjuvant Capecitabine Maintenance Therapy after Standard Chemotherapy for Triple-Negative Early Breast Cancer

A Lluch, H Gomez, M Ruiz-Borrego, J Bines, A Llombart, M Ramos, R Torres, JG Martins-Segalla, L Torrecillas, C. Barrios
Journal: Cancer Research
Cancer Res (2010) 70 (24_Supplement): P5-10-15.
DOI: https://doi.org/10.1158/0008-5472.SABCS10-P5-10-15
Published: 15 December 2010
View article
Journal Articles

Different Treatment Benefit for Luminal A and Luminal B Advanced Breast Cancinomas Receiving Aromatase Inhibitors.

M. Ruiz-Borrego, A. Moreno, J. Salvador, F. Carabantes, M. Torregrosa, T. Olmos, J. Martinez, J. de la Haba, M. Valero, E. Martinez, A. Santaballa, R. Hernández, A. Murias, A. Tortorella, C. Guzmán, J. Palacios
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 5141.
DOI: https://doi.org/10.1158/0008-5472.SABCS-09-5141
Published: 15 December 2009
View article